Share this video  

SITC 2022 | Collagen fiber + immune architecture as novel biomarker for gynecological cancers treated with IO

Anant Madabhushi, PhD, Emory University School of Medicine, Atlanta, GA, discusses the association between the combination of novel biomarkers of collagen fiber and immune architecture with clinically relevant outcomes in gynecological cancers treated with immunotherapy. An investigation of hematoxylin and eosin (H&E) images and collagen architecture lead to the identification of qualitive pattern that were associated with clinically relevant outcomes in the context of breast cancer. In a separate investigation, quantitative patterns relating to immune architecture was also highly correlated with outcome. Collagen biomarkers in combination with immune features were found to be associated with clinically relevant outcomes in gynecological cancers, better predicting response to immunotherapy than collagen fiber alone. This interview took place at the 37th Annual Meeting of the Society for Immunotherapy in Cancer (SITC 2022) in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.